Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical device company focused on cardiovascular and neuromodulation therapies, best known for its BackBeat CNT hypertension treatment platform. The company completed its business combination with Health Assurance Acquisition Corp, a blank-check company sponsored by Health Assurance Holdings — an entity backed by Humana and General Atlantic — which completed its IPO in 2020. Following the SPAC merger, which closed in early 2023, Orchestra BioMed filed a post-merger S-1 registration statement in October 2023, covering resale shares in the healthcare and medical devices sector. Visit SpacDesk and sign up for full filing history, deal analytics, and real-time tracking on OBIO and hundreds of other SPAC transactions.